Recently, Chen et al. [15] described direct involvement of ADAR editing in human hepatocellular carcinoma (HCC), showing how the transcripts of an oncoprotein degrader and confirmed contributor to HCC pathology, antizyme inhibitor 1 (AZIN1), are modified at specific sites by ADAR1, and that ADAR1 is commonly upregulated in HCC patient tumors resulting in even higher AZIN1 editing frequency and poorer prognosis. This evidence concerns the gene AZIN1 and hepatocellular carcinoma.